TICKERNERD
Menu
CVSAConsumer Defensive · Education & Training Services

CVSA Stock Forecast: Covista, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$130
+2.35% on the day

The 4 Wall Street analysts covering Covista, Inc. hold a median 12-month price target of $160 — +22.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 79 of 100 as at 8 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$4.3B
Ticker Nerd rank
79 / 100
Median analyst target
$160
Analysts covering
4
Revenue$501.4M+9.7% y/y
Operating income$96.5M
Net income$71.7M
Free cash flow$97.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+5.7%
1M
+4.1%
YTD
+25.9%
1Y
−11.0%
From 52W high
−15.4%
From 52W low
+45.8%
$89
$154
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CVSA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Covista, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
79 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
90
Quality
84
Issuance
65
Momentum
64
Accruals
63
Value
60
Growth
48
Volatility
47
Size
24

Revisions (90): Analysts have, on balance, been raising their forecasts.

Volatility (47): The share price moves around a lot.

Size (24): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CVSA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CVSA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$80$100$120$140$160$180Jan 26Apr 26Jul 26Oct 26CVSAHigh $175Median $160Low $140

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
3 Buy1 Hold0 Sell
Low $140Median $160High $175

The green dot is the last close — the median target sits +22.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 6 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
3 Sept 2026Truist SecuritiesDowngradeHold$140
8 June 2026Barrington ResearchMaintainsOutperform—
8 June 2026Barrington ResearchMaintainsOutperform$170
11 May 2026Truist SecuritiesMaintainsBuy—
17 Apr 2026Barrington ResearchMaintainsOutperform—
24 Mar 2026Truist SecuritiesInitiatesBuy—
2 Mar 2026Barrington ResearchMaintainsOutperform—
29 Jan 2026Barrington ResearchMaintainsOutperform—
31 Oct 2025Barrington ResearchMaintainsOutperform—
15 Oct 2025Barrington ResearchMaintainsOutperform—
23 Sept 2025Barrington ResearchMaintainsOutperform—
8 Aug 2025Barrington ResearchMaintainsOutperform$140 → $150
30 July 2025Barrington ResearchMaintainsOutperform$140
12 May 2025BMO CapitalMaintainsOutperform$115 → $132
9 May 2025Barrington ResearchMaintainsOutperform$120 → $140
23 Apr 2025JefferiesInitiatesBuy$135
15 Apr 2025Barrington ResearchMaintainsOutperform$120
3 Feb 2025BMO CapitalMaintainsOutperform$108 → $115
31 Jan 2025Barrington ResearchMaintainsOutperform$115 → $120
17 Jan 2025Barrington ResearchMaintainsOutperform$95 → $115

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CVSA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CVSA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, Covista, Inc. returned −11.0% against +16.2% for the S&P 500, dividends included.

CVSA vs S&P 500, last 12 monthsTotal return, rebased to 100
60708090100110120Jan 26Apr 26Jul 26Oct 26CVSAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CVSA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+1.8%
Analysts raising
2
Analysts cutting
1
Fundamentals

Covista, Inc. (CVSA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
17.0×

Cheaper than 42% of US stocks

Price / sales
2.2×

Cheaper than 49% of US stocks

Price / book
3.0×

Cheaper than 31% of US stocks

EV / EBITDA
10.9×

Cheaper than 34% of US stocks

Growth & margins
Revenue growth (YoY)
9.7%

Higher than 51% of US stocks

Earnings growth (YoY)
32.3%

Higher than 67% of US stocks

Gross margin
56.8%

Higher than 70% of US stocks

Operating margin
19.3%

Higher than 78% of US stocks

Net margin
12.9%

Higher than 75% of US stocks

Returns & dividend
Return on equity
18.6%

Higher than 79% of US stocks

Return on assets
8.5%

Higher than 89% of US stocks

Dividend yield
0.3%

Higher than 64% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Covista, Inc. (CVSA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Covista, Inc. has a market value of $4.3B and an enterprise value of $4.8B.

  • Revenue in the twelve months to 30 June 2026: $2.0B. The latest quarter grew 9.7% year on year.

  • Net income over the same four quarters: $251.6M, a 12.9% net margin.

  • Diluted earnings per share, trailing twelve months: $7.04.

  • Free cash flow in the twelve months to 30 June 2026: $392.7M, after $77.7M of capital spending.

  • Covista, Inc. spent $239.9M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 34.0M.

  • Trailing P/E: 17.0×; forward P/E: 12.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.28%, paying out 0% of earnings.

  • Covista, Inc. employs 4,736 people — $413K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Oct 2026

Data provided by Twelve Data

Peers

CVSA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelEducation & Training Services
CompanyMarket capTKN rank
CVSACovista, Inc.$4.3B
79
LOPEGrand Canyon Education, Inc.$4.3B
74
XXITwenty One Capital, Inc.$4.1B
3
LAURLaureate Education, Inc.$5.5B
81
LRNStride, Inc.$3.4B
62
MHMcGraw Hill, Inc.$2.6B
64
PRDOPerdoceo Education Corp.$2.1B
94

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Covista, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CVSA news & analysis

The DAISY Foundation® Names Walden University an Extraordinary Educational Partner

Business Wire · 1 Oct 2026positive

Walden University, a Covista (NYSE: CVSA) institution, has been named a DAISY Extraordinary Educational Partner by The DAISY Foundation. The partnership offers DAISY Honorees—nurses recognized for extraordinary, compassionate care—an affordable path to continue their educational and professional growth.

Why it matters — This recognition highlights Walden University's expanded role in nursing education and could strengthen the institution's reputation and appeal for a Covista watcher.

Covista Announces First Quarter Fiscal Year 2027 Conference Call

Business Wire · 29 Sept 2026neutral

Covista announced it will release its first quarter fiscal year 2027 results on Thursday, October 29, 2026, after market close, followed by a conference call at 4:00 p.m. CT the same day to discuss the results. Dial-in details for U.S. and international participants were provided.

Why it matters — CVSA watchers will want to know the date and logistics for the company's upcoming quarterly earnings release and conference call.

Here's Why Covista (CVSA) is a Strong Growth Stock

Zacks Investment Research · 23 Sept 2026positive

Zacks Investment Research highlights Covista (CVSA) as a strong growth stock, noting that investors can use the Zacks Style Scores to identify top-rated stocks based on investing style.

Why it matters — CVSA watchers would care because the article frames the company favorably as a top growth pick according to Zacks' screening methodology.

Covista (CVSA) is a Top-Ranked Value Stock: Should You Buy?

Zacks Investment Research · 16 Sept 2026positive

Zacks Investment Research identified Covista (CVSA) as a top-ranked value stock in a piece discussing its Zacks Style Scores. The excerpt promotes the Style Scores system for selecting market-beating stocks, though no specific CVSA details are provided.

Why it matters — A CVSA watcher would care because a top-ranked value designation from Zacks may raise the stock's visibility among value-focused investors.

Chamberlain University to Open Nashville Campus; Now Accepting Applications for January 2027 Cohort

Business Wire · 9 Sept 2026positive

Chamberlain University, a Covista institution, announced it will open a new campus in Nashville, Tennessee, its first location in the state, and is now accepting applications for the January 2027 cohort. The campus will offer day, evening, and weekend classes as part of the university's national expansion strategy to address the U.S. healthcare workforce shortage.

Why it matters — CVSA watchers would care because this expansion into a new state demonstrates continued growth of a key Covista institution and aligns with the company's strategy to directly address the U.S. healthcare workforce shortage.

FAQ

Frequently asked questions about CVSA stock

What is the CVSA stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Covista, Inc. have a median 12-month price target of $160, with estimates ranging from $140 to $175. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CVSA stock a buy right now?

Of the 4 analysts covering Covista, Inc., 3 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Covista, Inc. 79 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CVSA?

As at 8 Oct 2026, Covista, Inc. ranks 79 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (90 of 100).

Will CVSA stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +22.8% from the last close, and Ticker Nerd's factor model ranks Covista, Inc. 79 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CVSA stock forecast for 2030?

No analyst covering Covista, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CVSA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $140 to $175 over the next 12 months.

How has CVSA stock performed over the past year?

Covista, Inc. returned -11.0% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Covista, Inc. do?

Covista Inc. is a healthcare education company that provides post-secondary training through a portfolio of accredited institutions in the United States and select Caribbean markets.

What is the latest news on CVSA?

The most recent item we track (Business Wire, 1 Oct 2026): "The DAISY Foundation® Names Walden University an Extraordinary Educational Partner". Walden University, a Covista (NYSE: CVSA) institution, has been named a DAISY Extraordinary Educational Partner by The DAISY Foundation. The partnership offers DAISY Honorees—nurses recognized for extraordinary, compassionate care—an affordable path to continue their educational and professional growth.

Company

About Covista, Inc.

Covista Inc. is a healthcare education company that provides post-secondary training through a portfolio of accredited institutions in the United States and select Caribbean markets. Its current operations center on preparing students for careers in nursing, medicine, veterinary medicine, and other health-related professions through degree programs, online learning, and campus-based instruction. Covista’s business is organized around Chamberlain, Walden, and Medical and Veterinary segments, each serving different areas of professional education and workforce development. The company supports a broad student population with programs designed for flexible access, academic progression, and clinical preparation, making it an important provider in the healthcare education market. Based in Chicago, Illinois, Covista focuses on serving learners seeking specialized credentials for roles across the healthcare system.

CEO Mr. Stephen W. Beard J.D. · 4,736 employees · United States · https://www.covista.com